Phaxiam

About:

Phaxiam develops bacteriophage-based therapies to combat antimicrobial resistance in bacterial infections.

Website: https://phaxiam.com

Twitter/X: PHAXIAM

Top Investors: Bpifrance, FaDièse, Auriga Partners

Description:

Phaxiam is a clinical-stage biopharmaceutical company focused on developing innovative bacteriophage-based therapies to combat antimicrobial resistance. Specializing in the field of phage therapy, Phaxiam's research and development efforts are aimed at creating antibacterial treatments that utilize bacteriophage viruses, or phages, to target and eliminate resistant bacterial infections in humans. These infections are a growing concern in healthcare due to their ability to resist traditional antibiotics. By harnessing the specificity and effectiveness of phages, Phaxiam is working towards providing new solutions for serious bacterial infections that are difficult to treat with existing antibiotics.